ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Ann Med Res. 2018; 25(1): 70-75


Olanzapine-induced renal damage and metabolic side effects: the protective effect of thymoquinone

Sedat Bilgic, Deniz Tastemir Korkmaz, Sebile Azirak, Ayse Nilay Güvenc, Nevin Kocaman, Mehmet Kaya Ozer.



Abstract
Download PDF Cited by 5 ArticlesPost

Aim: The goal of the study is to examine the protective qualities of thymoquinone (TQ) against the side-effects of olanzapine (OLZ) in an experimental model in rat kidneys.
Material and Methods: Thirty five female Spraque-Dawley rats were divided into 5 groups (n=7): Control, OLZ, OLZ+TQ-1, OLZ+TQ-2, OLZ+TQ-3. All treatments were administered for two weeks by gavage. Two weeks administration of OLZ (4 mg/kg, once a day for the first week, 8 mg/kg once a day for the second week, p.o.) was given to all groups, except control. TQ was administered (25, 50, 100 mg/kg, once daily) by gastric tube. On treatment day 15, kidney tissues were removed for analysis.
Results: TQ increased the total antioxidant status (TAS) and decreased creatinine (Cr), blood urea nitrogen (BUN), oxidative stress index (OSI) and total oxidant status (TOS) levels significantly (p

Key words: Thymoquinone; Olanzapine; Adverse Effects; Kidney; Apoptosis.







Bibliomed Article Statistics

27
28
26
50
54
38
36
44
48
76
74
56
R
E
A
D
S

4

13

7

12

12

10

6

11

11

24

22

7
D
O
W
N
L
O
A
D
S
030405060708091011120102
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.